請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/31106
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蔡錦華(Ching-Hwa Tsai) | |
dc.contributor.author | Huey-Huey Chua | en |
dc.contributor.author | 蔡慧慧 | zh_TW |
dc.date.accessioned | 2021-06-13T02:30:06Z | - |
dc.date.available | 2009-02-02 | |
dc.date.copyright | 2007-02-02 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-01-25 | |
dc.identifier.citation | Adamson AL, Darr D, Holley-Guthrie E, Johnson RA, Mauser A, Swenson J and Kenney S (2000) Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol 74: 1224-1233.
Amit I, Yakir L, Katz M, Zwang Y, Marmor MD, Citri A, Shtiegman K, Alroy I, Tuvia S, Reiss Y, Roubini E, Cohen M, Wides R, Bacharach E, Schubert U and Yarden Y (2004) Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes Dev 18: 1737-1752. Andersson-Anvret M, Forsby N, Klein G and Henle W (1977) Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination. Int J Cancer 20: 486-494. Bishop N and Woodman P (2001) TSG101/mammalian VPS23 and mammalian VPS28 interact directly and are recruited to VPS4-induced endosomes. J Biol Chem 276: 11735-11742. Bouamr F, Melillo JA, Wang MQ, Nagashima K, de Los Santos M, Rein A and Goff SP (2003) PPPYVEPTAP motif is the late domain of human T-cell leukemia virus type 1 Gag and mediates its functional interaction with cellular proteins Nedd4 and Tsg101. J Virol 77: 11882-11895. Brummelkamp TR, Bernards R and Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553. Buisson M, Fleurent B, Mak M, Morand P, Chan L, Ng A, Guan M, Chin D and Seigneurin JM (1999) Novel immunoblot assay using four recombinant antigens for diagnosis of Epstein-Barr virus primary infection and reactivation. J Clin Microbiol 37: 2709-2714. Burgdorf S, Leister P and Scheidtmann KH (2004) TSG101 interacts with apoptosis-antagonizing transcription factor and enhances androgen receptor-mediated transcription by promoting its monoubiquitination. J Biol Chem 279: 17524-17534. Chan KC and Lo YM (2002) Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma. Semin Cancer Biol 12: 489-496. Chang LK, Chung JY, Hong YR, Ichimura T, Nakao M and Liu ST (2005) Activation of Sp1-mediated transcription by Rta of Epstein-Barr virus via an interaction with MCAF1. Nucleic Acids Res 33: 6528-6539. Chang Y, Chang SS, Lee HH, Doong SL, Takada K and Tsai CH (2004) Inhibition of the Epstein-Barr virus lytic cycle by Zta-targeted RNA interference. J Gen Virol 85: 1371-1379. Chang Y, Cheng SD and Tsai CH (2002) Chromosomal integration of Epstein-Barr virus genomes in nasopharyngeal carcinoma cells. Head Neck 24: 143-150. Chang Y, Lee HH, Chen YT, Lu J, Wu SY, Chen CW, Takada K and Tsai CH (2006) Induction of the early growth response 1 gene by Epstein-Barr virus lytic transactivator Zta. J Virol 80: 7748-7755. Chang Y, Tung CH, Huang YT, Lu J, Chen JY and Tsai CH (1999) Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes. J Virol 73: 8857-8866. Chasserot-Golaz S, Schuster C, Dietrich JB, Beck G and Lawrence DA (1988) Antagonistic action of RU38486 on the activity of transforming growth factor-beta in fibroblasts and lymphoma cells. J Steroid Biochem 30: 381-385. Chen LW, Chang PJ, Delecluse HJ and Miller G (2005) Marked variation in response of consensus binding elements for the Rta protein of Epstein-Barr virus. J Virol 79: 9635-9650. Chen MR, Yang JF, Wu CW, Middeldorp JM and Chen JY (1998) Physical association between the EBV protein EBNA-1 and P32/TAP/hyaluronectin. J Biomed Sci 5: 173-179. Chen YJ, Chen PH, Lin SY and Chang JG (1999) Analysis of aberrant transcription of TSG101 in hepatocellular carcinomas. Eur J Cancer 35: 302-308. Compagni A and Christofori G (2000) Recent advances in research on multistage tumorigenesis. Br J Cancer 83: 1-5. Countryman J and Miller G (1985) Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A 82: 4085-4089. Darr CD, Mauser A and Kenney S (2001) Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J Virol 75: 6135-6142. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825. El-Guindy AS and Miller G (2004) Phosphorylation of Epstein-Barr virus ZEBRA protein at its casein kinase 2 sites mediates its ability to repress activation of a viral lytic cycle late gene by Rta. J Virol 78: 7634-7644. Faggioni A, Zompetta C, Grimaldi S, Barile G, Frati L and Lazdins J (1986) Calcium modulation activates Epstein-Barr virus genome in latently infected cells. Science 232: 1554-1556. Farina A, Feederle R, Raffa S, Gonnella R, Santarelli R, Frati L, Angeloni A, Torrisi MR, Faggioni A and Delecluse HJ (2005) BFRF1 of Epstein-Barr virus is essential for efficient primary viral envelopment and egress. J Virol 79: 3703-3712. Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W and Delecluse HJ (2000) The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 19: 3080-3089. Feng GH, Lih CJ and Cohen SN (2000) TSG101 protein steady-state level is regulated posttranslationally by an evolutionarily conserved COOH-terminal sequence. Cancer Res 60: 1736-1741. Fujimuro M and Yokosawa H (2005) Production of antipolyubiquitin monoclonal antibodies and their use for characterization and isolation of polyubiquitinated proteins. Methods Enzymol 399: 75-86. Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Cote M, Rich RL, Myszka DG and Sundquist WI (2001) Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107: 55-65. Ghosh A, Stewart D and Matlashewski G (2004) Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24: 7987-7997. Giglio S, Mancini F, Gentiletti F, Sparaco G, Felicioni L, Barassi F, Martella C, Prodosmo A, Iacovelli S, Buttitta F, Farsetti A, Soddu S, Marchetti A, Sacchi A, Pontecorvi A and Moretti F (2005) Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. Cancer Res 65: 9687-9694. Gong M and Kieff E (1990) Intracellular trafficking of two major Epstein-Barr virus glycoproteins, gp350/220 and gp110. J Virol 64: 1507-1516. Granato M, Farina A, Gonnella R, Santarelli R, Frati L, Faggioni A and Angeloni A (2006) Regulation of the expression of the Epstein-Barr virus early gene BFRF1. Virology 347: 109-116. Gruffat H, Manet E, Rigolet A and Sergeant A (1990) The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. Nucleic Acids Res 18: 6835-6843. Hadar T, Rahima M, Kahan E, Sidi J, Rakowsky E, Sarov B and Sarov I (1986) Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients. J Med Virol 20: 329-339. Hall AH and Alexander KA (2003) RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J Virol 77: 6066-6069. Hardwick JM, Lieberman PM and Hayward SD (1988) A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol 62: 2274-2284. Hewitt EW, Duncan L, Mufti D, Baker J, Stevenson PG and Lehner PJ (2002) Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation. EMBO J 21: 2418-2429. Hittelman AB, Burakov D, Iniguez-Lluhi JA, Freedman LP and Garabedian MJ (1999) Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. EMBO J 18: 5380-5388. Holley-Guthrie EA, Quinlivan EB, Mar EC and Kenney S (1990) The Epstein-Barr virus (EBV) BMRF1 promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J Virol 64: 3753-3759. Hoppe T (2005) Multiubiquitylation by E4 enzymes: 'one size' doesn't fit all. Trends Biochem Sci 30: 183-187. Hsu MM (1992) Clinical application of Epstein-Barr virus serology for patients with nasopharyngeal carcinoma. In Immunology in Otology, Rhinology and Laryngology, McCabe BF VJ, Mogi G (ed), pp 303-308. Amsterdam, New York: Kugler Publications. Hsu TY, Chang Y, Wang PW, Liu MY, Chen MR, Chen JY and Tsai CH (2005) Reactivation of Epstein-Barr virus can be triggered by an Rta protein mutated at the nuclear localization signal. J Gen Virol 86: 317-322. Huang J, Liao G, Chen H, Wu FY, Hutt-Fletcher L, Hayward GS and Hayward SD (2006) Contribution of C/EBP proteins to Epstein-Barr virus lytic gene expression and replication in epithelial cells. J Virol 80: 1098-1109. Huang YT, Sheen TS, Chen CL, Lu J, Chang Y, Chen JY and Tsai CH (1999) Profile of cytokine expression in nasopharyngeal carcinomas: a distinct expression of interleukin 1 in tumor and CD4+ T cells. Cancer Res 59: 1599-1605. Ismaili N, Blind R and Garabedian MJ (2005) Stabilization of the unliganded glucocorticoid receptor by TSG101. J Biol Chem 280: 11120-11126. Johannsen E, Luftig M, Chase MR, Weicksel S, Cahir-McFarland E, Illanes D, Sarracino D and Kieff E (2004) Proteins of purified Epstein-Barr virus. Proc Natl Acad Sci U S A 101: 16286-16291. Kenney S, Holley-Guthrie E, Mar EC and Smith M (1989) The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators. J Virol 63: 3878-3883. Kieff E and Rickinson AB (2001) Epstein-Barr virus and its replication. In Fields virology, Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B and Straus SE (eds) pp 2541-2548. Philadelphia, PA: Lippincott Williams and Wilkins. Kijima T, Kinukawa N, Gooding WE and Uno M (2001) Association of Epstein-Barr virus with tumor cell proliferation: clinical implication in nasopharyngeal carcinoma. Int J Oncol 18: 479-485. Klaes R, Kloor M, Willeke F, Melsheimer P, von Knebel Doeberitz M and Ridder R (1999) Significant increase of a specific variant TSG101 transcript during the progression of cervical neoplasia. Eur J Cancer 35: 733-737. Koonin EV and Abagyan RA (1997) TSG101 may be the prototype of a class of dominant negative ubiquitin regulators. Nat Genet 16: 330-331. Krempler A, Henry MD, Triplett AA and Wagner KU (2002) Targeted deletion of the Tsg101 gene results in cell cycle arrest at G1/S and p53-independent cell death. J Biol Chem 277: 43216-43223. Kryworuckho M, Diaz-Mitoma F and Kumar A (1995) CD44 isoforms containing exons V6 and V7 are differentially expressed on mitogenically stimulated normal and Epstein-Barr virus-transformed human B cells. Immunology 86: 41-48. Kurilla MG, Heineman T, Davenport LC, Kieff E and Hutt-Fletcher LM (1995) A novel Epstein-Barr virus glycoprotein gp150 expressed from the BDLF3 open reading frame. Virology 209: 108-121. Lagenaur LA and Palefsky JM (1999) Regulation of Epstein-Barr virus promoters in oral epithelial cells and lymphocytes. J Virol 73: 6566-6572. Li JS, Zhou BS, Dutschman GE, Grill SP, Tan RS and Cheng YC (1987) Association of Epstein-Barr virus early antigen diffuse component and virus-specified DNA polymerase activity. J Virol 61: 2947-2949. Li L and Cohen SN (1996) Tsg101: a novel tumor susceptibility gene isolated by controlled homozygous functional knockout of allelic loci in mammalian cells. Cell 85: 319-329. Li L, Li X, Francke U and Cohen SN (1997) The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer. Cell 88: 143-154. Li L, Liao J, Ruland J, Mak TW and Cohen SN (2001) A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc Natl Acad Sci U S A 98: 1619-1624. Li Z, Pan L, Cesarman E and Knowles DM (2003) Alterations of mRNA splicing in primary effusion lymphomas. Leuk Lymphoma 44: 833-840. Lin DY, Fang HI, Ma AH, Huang YS, Pu YS, Jenster G, Kung HJ and Shih HM (2004a) Negative modulation of androgen receptor transcriptional activity by Daxx. Mol Cell Biol 24: 10529-10541. Lin JC, Shaw JE, Smith MC and Pagano JS (1979) Effect of 12-O-tetradecanoyl-phorbol-13-acetate on the replication of Epstein-Barr virus. I. Characterization of viral DNA. Virology 99: 183-187. Lin JC, Sista ND, Besencon F, Kamine J and Pagano JS (1991) Identification and functional characterization of Epstein-Barr virus DNA polymerase by in vitro transcription-translation of a cloned gene. J Virol 65: 2728-2731. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS and Jiang RS (2004b) Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350: 2461-2470. Liu C, Sista ND and Pagano JS (1996) Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F. J Virol 70: 2545-2555. Liu P and Speck SH (2003) Synergistic autoactivation of the Epstein-Barr virus immediate-early BRLF1 promoter by Rta and Zta. Virology 310: 199-206. Liu RT, Huang CC, You HL, Chou FF, Hu CC, Chao FP, Chen CM and Cheng JT (2002) Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas. Oncogene 21: 4830-4837. Liu XQ, Chen HK, Zhang XS, Pan ZG, Li A, Feng QS, Long QX, Wang XZ and Zeng YX (2003) Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. Int J Cancer 106: 60-65. Lo KW and Huang DP (2002) Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 12: 451-462. Lo YF, Chen TC, Chen SC and Chao CC (2000) Aberrant expression of TSG101 in Taiwan Chinese breast cancer. Breast Cancer Res Treat 60: 259-266. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ and Huang DP (1999) Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59: 1188-1191. Lu CC, Jeng YY, Tsai CH, Liu MY, Yeh SW, Hsu TY and Chen MR (2006) Genome-wide transcription program and expression of the Rta responsive gene of Epstein-Barr virus. Virology 345: 358-372. Lu J, Chen SY, Chua HH, Liu YS, Huang YT, Chang Y, Chen JY, Sheen TS and Tsai CH (2000) Upregulation of tyrosine kinase TKT by the Epstein-Barr virus transactivator Zta. J Virol 74: 7391-7399. Lu J, Chua HH, Chen SY, Chen JY and Tsai CH (2003a) Regulation of matrix metalloproteinase-1 by Epstein-Barr virus proteins. Cancer Res 63: 256-262. Lu JJ, Chen JY, Hsu TY, Yu WC, Su IJ and Yang CS (1996) Induction of apoptosis in epithelial cells by Epstein-Barr virus latent membrane protein 1. J Gen Virol 77 ( Pt 8): 1883-1892. Lu Q, Hope LW, Brasch M, Reinhard C and Cohen SN (2003b) TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation. Proc Natl Acad Sci U S A 100: 7626-7631. Luka J, Kallin B and Klein G (1979) Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94: 228-231. Mackett M, Conway MJ, Arrand JR, Haddad RS and Hutt-Fletcher LM (1990) Characterization and expression of a glycoprotein encoded by the Epstein-Barr virus BamHI I fragment. J Virol 64: 2545-2552. Manet E, Rigolet A, Gruffat H, Giot JF and Sergeant A (1991) Domains of the Epstein-Barr virus (EBV) transcription factor R required for dimerization, DNA binding and activation. Nucleic Acids Res 19: 2661-2667. Martin-Serrano J, Zang T and Bieniasz PD (2001) HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med 7: 1313-1319. Mercatante D and Kole R (2000) Modification of alternative splicing pathways as a potential approach to chemotherapy. Pharmacol Ther 85: 237-243. Mettenleiter TC (2004) Budding events in herpesvirus morphogenesis. Virus Res 106: 167-180. Moyret-Lalle C, Duriez C, Van Kerckhove J, Gilbert C, Wang Q and Puisieux A (2001) p53 induction prevents accumulation of aberrant transcripts in cancer cells. Cancer Res 61: 486-488. Muromoto R, Sugiyama K, Yamamoto T, Oritani K, Shimoda K and Matsuda T (2004) Physical and functional interactions between Daxx and TSG101. Biochem Biophys Res Commun 316: 827-833. Nemerow GR, Mold C, Schwend VK, Tollefson V and Cooper NR (1987) Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol 61: 1416-1420. Niedobitek G, Agathanggelou A and Nicholls JM (1996) Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol 7: 165-174. Oh Y, Proctor ML, Fan YH, Su LK, Hong WK, Fong KM, Sekido YS, Gazdar AF, Minna JD and Mao L (1998) TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer. Oncogene 17: 1141-1148. Ponting CP, Cai YD and Bork P (1997) The breast cancer gene product TSG101: a regulator of ubiquitination? J Mol Med 75: 467-469. Pornillos O, Alam SL, Rich RL, Myszka DG, Davis DR and Sundquist WI (2002) Structure and functional interactions of the Tsg101 UEV domain. EMBO J 21: 2397-2406. Quinlivan EB, Holley-Guthrie EA, Norris M, Gutsch D, Bachenheimer SL and Kenney SC (1993) Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res 21: 1999-2007. Raab-Traub N (2002) Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12: 431-441. Ragoczy T, Heston L and Miller G (1998) The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol 72: 7978-7984. Ragoczy T and Miller G (1999) Role of the Epstein-Barr virus RTA protein in activation of distinct classes of viral lytic cycle genes. J Virol 73: 9858-9866. Ragoczy T and Miller G (2001) Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites. J Virol 75: 5240-5251. Reeves JD and Piefer AJ (2005) Emerging drug targets for antiretroviral therapy. Drugs 65: 1747-1766. Reischl U, Gerdes C, Motz M and Wolf H (1996) Expression and purification of an Epstein-Barr virus encoded 23-kDa protein and characterization of its immunological properties. J Virol Methods 57: 71-85. Serafini-Cessi F, Malagolini N, Nanni M, Dall'Olio F, Campadelli-Fiume G, Tanner J and Kieff E (1989) Characterization of N- and O-linked oligosaccharides of glycoprotein 350 from Epstein-Barr virus. Virology 170: 1-10. Serio TR, Kolman JL and Miller G (1997) Late gene expression from the Epstein-Barr virus BcLF1 and BFRF3 promoters does not require DNA replication in cis. J Virol 71: 8726-8734. Shanley TP, Warner RL and Ward PA (1995) The role of cytokines and adhesion molecules in the development of inflammatory injury. Mol Med Today 1: 40-45. Shen H, Pan Y, Han Z, Hong L, Liu N, Han S, Yao L, Xie H, Zhaxi C, Shi Y and Fan D (2004) Reversal of multidrug resistance of gastric cancer cells by downregulation of TSG101 with TSG101siRNA. Cancer Biol Ther 3: 561-565. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y and Takada K (1994) Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol 68: 6069-6073. Shimizu N, Yoshiyama H and Takada K (1996) Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells. J Virol 70: 7260-7263. Sinclair AJ, Brimmell M, Shanahan F and Farrell PJ (1991) Pathways of activation of the Epstein-Barr virus productive cycle. J Virol 65: 2237-2244. Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, Toiber D, Thanaraj TA and Soreq H (2005) Function of alternative splicing. Gene 344: 1-20. Stickeler E, Kittrell F, Medina D and Berget SM (1999) Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 18: 3574-3582. Sun Y, Hegamyer G, Cheng YJ, Hildesheim A, Chen JY, Chen IH, Cao Y, Yao KT and Colburn NH (1992) An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 89: 6516-6520. Sun Z, Pan J, Hope WX, Cohen SN and Balk SP (1999) Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300. Cancer 86: 689-696. Surjit M, Oberoi R, Kumar R and Lal SK (2006) Enhanced alpha1 microglobulin secretion from Hepatitis E virus ORF3-expressing human hepatoma cells is mediated by the tumor susceptibility gene 101. J Biol Chem 281: 8135-8142. Swenson JJ, Holley-Guthrie E and Kenney SC (2001) Epstein-Barr virus immediate-early protein BRLF1 interacts with CBP, promoting enhanced BRLF1 transactivation. J Virol 75: 6228-6234. Thompson MP and Kurzrock R (2004) Epstein-Barr virus and cancer. Clin Cancer Res 10: 803-821. Thrower JS, Hoffman L, Rechsteiner M and Pickart CM (2000) Recognition of the polyubiquitin proteolytic signal. EMBO J 19: 94-102. Triantos D, Porter SR, Scully C and Teo CG (1997) Oral hairy leukoplakia: clinicopathologic features, pathogenesis, diagnosis, and clinical significance. Clin Infect Dis 25: 1392-1396. Tsai CH and Glaser R (1991) A comparison of Epstein-Barr virus specific proteins expressed by three Epstein-Barr virus isolates using specific monoclonal antibodies. Intervirology 32: 376-382. Tsai CH, Liu MT, Chen MR, Lu J, Yang HL, Chen JY and Yang CS (1997) Characterization of Monoclonal Antibodies to the Zta and DNase Proteins of Epstein-Barr Virus. J Biomed Sci 4: 69-77. Turpin E, Dalle B, de Roquancourt A, Plassa LF, Marty M, Janin A, Beuzard Y and de The H (1999) Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers. Oncogene 18: 7834-7837. Urier G, Buisson M, Chambard P and Sergeant A (1989) The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites. EMBO J 8: 1447-1453. von Schwedler UK, Stuchell M, Muller B, Ward DM, Chung HY, Morita E, Wang HE, Davis T, He GP, Cimbora DM, Scott A, Krausslich HG, Kaplan J, Morham SG and Sundquist WI (2003) The protein network of HIV budding. Cell 114: 701-713. Wagner KU, Dierisseau P, Rucker EB, Robinson GW and Hennighausen L (1998) Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants. Oncogene 17: 2761-2770. Wagner KU, Krempler A, Qi Y, Park K, Henry MD, Triplett AA, Riedlinger G, Rucker IE and Hennighausen L (2003) Tsg101 is essential for cell growth, proliferation, and cell survival of embryonic and adult tissues. Mol Cell Biol 23: 150-162. Watanabe M, Yanagi Y, Masuhiro Y, Yano T, Yoshikawa H, Yanagisawa J and Kato S (1998) A putative tumor suppressor, TSG101, acts as a transcriptional suppressor through its coiled-coil domain. Biochem Biophys Res Commun 245: 900-905. Weissman AM (2001) Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2: 169-178. Wollerton MC, Gooding C, Wagner EJ, Garcia-Blanco MA and Smith CW (2004) Autoregulation of polypyrimidine tract binding protein by alternative splicing leading to nonsense-mediated decay. Mol Cell 13: 91-100. Yin Y, Stephen CW, Luciani MG and Fahraeus R (2002) p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 4: 462-467. Yuan J, Cahir-McFarland E, Zhao B and Kieff E (2006) Virus and cell RNAs expressed during Epstein-Barr virus replication. J Virol 80: 2548-2565. Yung WC, Sham JS, Choy DT and Ng MH (1995) ras mutations are uncommon in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol 31B: 399-400. Zhong Q, Chen Y, Jones D and Lee WH (1998) Perturbation of TSG101 protein affects cell cycle progression. Cancer Res 58: 2699-2702. Zhu G, Gilchrist R, Borley N, Chng HW, Morgan M, Marshall JF, Camplejohn RS, Muir GH and Hart IR (2004) Reduction of TSG101 protein has a negative impact on tumor cell growth. Int J Cancer 109: 541-547. zur Hausen H, O'Neill FJ, Freese UK and Hecker E (1978) Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature 272: 373-375. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/31106 | - |
dc.description.abstract | 於細胞癌化過程中,其前體信使核糖核酸 (pre-mRNA)之剪接(splicing) 常喪失了正常精確的自我調節能力,以致出現異常剪接 (aberrant splicing)現象;Tumor susceptibility gene 101 (TSG101) pre-mRNA之剪接即是此過程中常受影響的範例之一。在許多種癌組織細胞中,TSG101 mRNA的表現,除了其全長的TSG101 mRNA外,亦可同時偵測到其它截形(truncated)的TSG101 mRNA同質體 (isoform);尤其是剪除TSG101核苷酸第154至1054 之mRNA (於後稱為TSG101-247),更是TSG101諸多異常剪接產物中出現頻率最高的一員。本研究發現鼻咽癌病理組織亦不例外,我們在其中也偵查到TSG101-247的表現。獨特的是,TSG101-247在鼻咽癌細胞株中的表現與EBV的感染息息相關,尤其是EBV進入溶裂期(lytic cycle)時,TSG101-247在該細胞中的表現量較EBV滞留在潛伏期(latent state)者更勝一籌。由基因轉染試驗顯示,EBV 的病毒蛋白質EBNA1,Zta 與Rta會干預TSG101 mRNA的剪接並促成TSG101-247產生。
在功能上,我們發現TSG101-247可增強TSG101蛋白質的穩定性(stability),其中關鍵機制在於TSG101-247可抑制TSG101的多次泛素化(polyubiquitination),進而使TSG101不被蛋白解體(proteasome)分解。TSG101-247此功能需待其轉譯成蛋白質後方能執行,因若將TSG101-247 的啟動密碼子(start codon) AUG突變成AAA後,TSG101-247無法轉譯成蛋白質,其穩定TSG101的能力也隨既消失。再者,若將TSG101-247蛋白質上的離氨基酸基(Lysine residue, K)置換成精氨酸(Arginine, R),使其無法與泛素(ubiquitin, Ub)結合,如此也會導致TSG101-247穩定TSG101的能力喪失。可見TSG101-247蛋白質與Ub的結合能力攸關其是否能穩定TSG101。深入分析,我們發現TSG101-247實與TSG101競爭結合TSG101專屬的E3 Ub ligase,稱TSG101-associated ligase (Tal)。一旦TSG101-247結合了Tal之後,所引發的結果與TSG101相似---TSG101-247會被多次泛素化。經由此途徑,TSG101-247不僅增強了TSG101蛋白質的穩定性,同時亦強化了TSG101在細胞中的機能活性。因表現TSG101-247的細胞,其中TSG101抑制雄性荷爾蒙受體(androgen receptor)活化基因表現以及TSG101刺激癌細胞生長的能力均顯著增強。針對EBV而言,我們發現TSG101-247透過強化TSG101蛋白質的穩定性亦可增進EBV晚期基因(late gene)的表現。 有鑒於此,我們開始探究EBV是否利用TSG101來協助其發展溶裂期並產出子代。採用微小核糖核酸干擾(small interfering RNA, siRNA)策略剔除細胞中內質性TSG101,隨後再利用化學藥物激發EBV溶裂期之進行。透過微陣列(microarray)實驗法發現多種EBV晚期基因,會因TSG101的缺乏而表現受到阻滯,包括︰ BcLF1,BDLF3,BILF2,BLLF1及BLRF2等病毒基因。進一步,由reporter gene assay實驗結果獲悉此五個晚期基因的活化主要皆受EBV溶裂期的轉活化子Rta調控。經TSG101 siRNA 減除TSG101後,Rta活化此五個晚期基因的能力便顯著下降。然而,若增加細胞中TSG101的表現量, Rta啟動這些晚期基因表現的能力則隨之遞增。其中的作用機制可能是Rta透過增加TSG101蛋白質在核中的表現量,增大了其與TSG101蛋白質在核中的結合機會。Rta藉此結合使其順利地裝載在EBV晚期基因的啟動子(promoter)上,進而活化了EBV晚期基因的表現。若TSG101此時被siRNA剔除,則Rta結合到EBV晚期基因 啟動子上的能力將嚴重受損,病毒的晚期基因產物因此而不再表現,病毒粒子的合成也告失敗。 總而言之,於本研究我們首要提出TSG101的異常剪接產物TSG101-247具備了穩定 TSG101蛋白質的獨特功能,並藉此增進TSG101在細胞中的機能活性。另,本研究亦揭發了TSG101在Rta活化EB 病毒晚期基因上的重要貢獻。此結果顯示,DNA病毒與RNA病毒一樣都會奪取細胞中的TSG101來協助他們繁衍子代。唯二者利用TSG101促成病毒粒子產生的方式可能不一樣。DNA病毒如EBV利用TSG101協助其表現晚期基因進而產生病毒顆粒。然而,enveloped RNA病毒則藉用TSG101運送其晚期基因產物至細胞膜表面以便組裝成病毒粒子。 | zh_TW |
dc.description.abstract | The fidelity of splicing is lost in most cancers resulting in aberrant splicing of pre-mRNA. Tumor susceptibility gene 101 (TSG101) is a frequent target of these splicing defects, as evidenced by co-expression of its full-length transcript with truncated mRNA isoforms in a variety of human cancers. This study demonstrates that nasopharyngeal carcinomas (NPC) tissues express an abundance of TSG101 transcripts with nucleotides 154-1054 deleted (designated TSG101-247). In particular, Epstein-Barr virus (EBV)-infected NPC cells harbor this splice variant, and the incidence of expression of this variant increases during the EBV lytic cycle. The EBV-encoded viral proteins, EBNA1, Zta and Rta, are demonstrated as crucial factors that involved in the enhancement of TSG101 aberrant splicing. Mechanistically, TSG101-247 stabilizes TSG101 by impairing its polyubiquitination and subsequent proteasomal degradation. Mutation of the TSG101-247 start codon showed that the variant protein, and not the RNA, blocks polyubiquitination. In addition, mutation of lysine residues in TSG101-247 that particularly disrupt the conjugation of ubiquitin (Ub) moiety negates this effect, resulting in rapid turnover of TSG101 and suggesting a requirement for Ub-chain attachment in the stabilization of TSG101 mediated by TSG101-247. To explore the underlying mechanism further, we demonstrated that TSG101-247 prevents the polyubiquitination of TSG101 by binding competitively to the TSG101-associated ligase (Tal), an E3 Ub ligase. Consequently, TSG101-247 augments the functional activities of TSG101, having a negative effect on androgen receptor-induced gene activation and a positive effect on cell proliferation. Moreover, TSG101-247 enhances TSG101-induced EB viral late gene expression.
The requirement of TSG101 protein for EB virion formation has been established herein by an RNA interference assay. Results from an EBV DNA array reveal that depletion of TSG101 potently inhibits the transcription of five Rta-responsive EBV late genes, BcLF1, BDLF3, BILF2, BLLF1 and BLRF2. Rta is an EBV encoded immediate-early protein, which governs the reactivation of the viral lytic program by transactivating a cascade of lytic gene expression. TSG101 is involved in the mechanism underlying the expression of these EBV late genes mediated by Rta, seeing that depletion of TSG101 impairs Rta transactivation of these late promoters severely. Moreover, a concordant augmentation of Rta transactivating activity is observed when TSG101 is over-expressed following ectopic transfection. Mechanistically, Rta causes the TSG101 protein to accumulate principally in the nuclei, wherein both these proteins interact and are recruited onto the viral promoters. Of note, TSG101 is crucial for efficient binding of Rta onto these late promoters. As a result, cells with defective TSG101 fail to express late viral proteins, leading to a decrease in the yield of virus particles. Altogether, we provide the first functional evidence of the splicing variant of TSG101. TSG101-247 is a novel regulator of TSG101 stability thereby facilitating role of TSG101 in cellular compartment. In addition, the contribution of TSG101 to Rta-mediated late gene activation is of great importance for completion of the EBV productive lytic cycle. These observations consolidate a role of TSG101 in the replication of EBV, a DNA virus, that differs from that for RNA viruses, where TSG101 aids mainly in the endosomal sorting of enveloped late viral proteins for assembly at the plasma membrane. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T02:30:06Z (GMT). No. of bitstreams: 1 ntu-96-F87445112-1.pdf: 4120574 bytes, checksum: be7e729966a4fb9a30832edcab326697 (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 中文摘要 I
Abstract III Abbreviations V Contents VII Chapter 1: Introduction 1 1.1 Tumor susceptibility gene 101 1 1.2 Nasopharyngeal carcinomas 4 1.3 Epstein-Barr virus 5 Chapter 2: Aims of the study 9 Chapter 3: Materials and methods 10 3.1 Biopsy samples 10 3.2 Cell culture 10 3.3 Plasmid construction 11 3.4 Transfection 13 3.5 RNA and DNA extraction 13 3.6 Reverse transcription-PCR 14 3.7 Northern blot analysis 15 3.8 Microarray analysis 16 3.9 Reporter gene assay 16 3.10 Pulse-chase assay 17 3.11 Isolation of detergent soluble and insoluble fractions 17 3.12 Subcellular fractionation 17 3.13 Co-immunoprecipitation 18 3.14 Western blot analysis 18 3.15 Immunofluoresence assay 19 3.16 [3H]-thymidine incorporation assay for cell proliferation 20 3.17 Nuclear extraction 20 3.18 DNA affinity protein binding assay 21 3.19 Electrophoretic mobility shift assay 21 3.20 Isolation of EB viral particles 22 3.21 Sandwich ELISA 22 3.22 Quantification of EBV copy 23 3.23 DNA extraction and PCR assay for secreted EBV 24 3.24 Statistical analysis 24 Chapter 4: Results 25 4.1 Specific expression of aberrantly spliced TSG101 products in NPC tissues 25 4.2 EBV infection promotes the generation of TSG101-247 and further enhancement is observed upon EBV reactivation 26 4.3 EBV products are responsible for generation of the TSG101-247 splice variant 28 4.4 Expression of TSG101-247 links to the increasing levels of TSG101 proteins 28 4.5 TSG101-247 prolongs the half-life of TSG101 protein 29 4.6 TSG101-247 stabilizes and protects TSG101 from Ub-dependent proteolysis, an effect requiring its protein product 30 4.7 Cellular expression of variant TSG101-247 32 4.8 TSG101-247 competes with TSG101 for poly-Ub binding 32 4.9 TSG101-247 competes with TSG101 for binding Tal 34 4.10 TSG101-247 functionally augments the biological activities of TSG101 by increasing the stability of the protein 34 4.11 TSG101 is essential for EBV late lytic progression and virion release 36 4.12 Enhancement of BcLF1 and BLLF1 expressions by TSG101 and TSG101-247 37 4.13 Depletion of TSG101 retards EBV late gene transcription 38 4.14 TSG101 crucially augments the transactivation ability of Rta 39 4.15 EBV Rta binds TSG101 40 4.16 N-terminus of Rta mediates the binding of the TSG101 UEV domain 41 4.17 Rta co-localizes with TSG101 in the nucleus 42 4.18 Rta increases the nuclear TSG101 protein level 43 4.19 TSG101 facilitates Rta binding to the promoters of EBV late gene 44 4.20 TSG101 UEV domain is importance for recruitment of TSG101 onto BLRF2 promoter that resulting in activation of BLRF2 46 4.21 Extensive impact of TSG101 on various gene transactivation mediated by Rta 47 4.22 EBV induction leads to an increasing amount of TSG101 not only in the nucleus, but also the cytosolic compartment 48 Chapter 5: Discussion 50 5.1 Functional importance of TSG101-247 splice variant in regulating TSG101 50 5.2 Generation of TSG101-247 splice variant—an effect caused by viral factors 50 5.3 Molecular mechanism of TSG101-247 action—a pathway involving ubiquitination 52 5.4 Influence of TSG101-247 variant—from the perspective of TSG101 biological role 53 5.5 Importance of TSG101 in EB viral particle formation—a comparison with RNA virus 55 5.6 Mechanism of EBV exploiting TSG101—a pathway mediated by the viral transactivator Rta 56 5.7 A novel role of TSG101 in Rta-induced viral gene activation 59 5.8 Conclusion 60 Future perspectives 62 Tables 64 Figures 70 References 100 Curriculum vitae 112 | |
dc.language.iso | en | |
dc.title | TSG101蛋白質之穩定性受其剪接變異體作用並藉此影響Epstein-Barr病毒晚期基因的轉錄 | zh_TW |
dc.title | Stabilization of TSG101 protein by its splice variant and the impact on Epstein-Barr viral late gene transcription | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 黃麗華,吳慧琳,陳美如,許金玉,張雯,鄭子豪 | |
dc.subject.keyword | Epstein-Barr 病毒,晚期基因,Rta,剪接,轉錄,Tumor susceptibility gene 101 (TSG101),泛素, | zh_TW |
dc.subject.keyword | Epstein-Barr virus (EBV),Late gene,Rta,Splicing,Transcription,Tumor susceptibility gene 101 (TSG101),Ubiquitin (Ub), | en |
dc.relation.page | 113 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2007-01-25 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 4.02 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。